doi:10.1592/phco.24.9.856.36106 2Wulf NR, Matuszewski KA
They include minimal water retention and irritation at the injection site
The submission is supported by the SURPASS CVOT trial, which showed that Mounjaro reduced the risk of MACE including cardiovascular (CV) death, heart attack, or stroke by 8% compared with dulaglutide (Trulicity
10%), while 13% of Hispanic adults say they have taken these drugs
Pioglitazone, a diabetes medication, may benefit selected patients with biopsy-proven NASH, but is also specialist-led and off-label , with potential risks including weight gain, fluid retention, heart failure, and increased fracture risk